Abstract:Abstract Purpose: Neoadjuvant chemotherapy may provide early indication of treatment response. Pathologic complete response (pCR) rate is a surrogate measure of disease-free and overall survival. Anthracycline remain an important component of chemotherapy regimen for breast cancer (BC), while adding taxane confers additional pCR rate. However the combination of anthracycline and trastuzumab remain controversial due to potential increased risk of cardiac event. This trial was designed to compare the efficacy and safety between epirubicin(E) and carboplatin(C) in combination with paclitaxel(P) and trastuzumab(H). Methods: In 13 medical centers, 100 Patients with HER-2/neu immunohistochemistry (IHC) 3+ or FISH-amplified untreated breast cancer, baseline left ventricular ejection fraction (LVEF) of ≥ 55%, ECOG0/1, were enrolled from Sep 2011 to May 2012. Study medication was as follows: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg) and Pacitaxel (75 mg/m2) weekly combine with Carbopatin (AUC 2) weekly for PCH group or Epirubicin(75 mg/m2) every 3 weeks for PEH group. Patients were recommended to receive 4 or more cycles. The primary endpoint was pCR in the breast and axilla. Secondary endpoints included clinical response, safety. Results: By Aug 16, 2012, 50 patients were randomly assigned to receive PCH regimen and 50 to receive PEH regimen. 49 belonged to TNM stage II, 51 belonged to TNM stage III. The median age was 48 years (range 29 to 65 years). 87 patients completed at least 4 cycles neoadjuvant therapy and then received surgical treatment. pCR in the breast/axilla were found in 38 patients (43.7%; 95% confidence interval [CI]: 33.3%-54.1%). There was no statistic significant difference in PCH and PEH regimen (39.1% vs. 48.8%; p = 0.365). However, PEH regimen achieved significant higher pCR in luminal-B (HER2-poitive) subgroup compared with PCH regimen (55.0% vs. 24.0%; p = 0.033), but not in ERBB2+ subgroup (42.9% vs. 57.1%; p = 0.355). Median LVEF at baseline was 66.0% (range 56.5% to 83.0%), having was no difference between PCH and PEH group (67.0% vs. 65.0%). After 2 cycles in 82 patients, the median LVEF was 64.7% (range 55.0% to 84.0%), there was no difference of LVEF (63.0% vs.66.0%). After 4 cycles in 80 patients, the median LVEF was 66.0% (range 53.0% to 76.0%), no difference was observed between PCH and PEH group (63.0% vs. 66.2%). 8 patients had LVEF decreases of over 10% after 2 cycles, of which 5 patients in PCH group and 3 patients in PEH group. After more than 4 cycles, 3 patients in PCH group and 1 patient in PEH group had LVEF decreases of over 10.0% compared with baseline. No patient experienced LVEF of less than 50% and congestive heart failure (CHF). There was no cardiac death reported. Conclusion: Both PCH and PEH regimens as neoadjuvant chemotherapy have the similar pCR rate for breast cancer patients with HER2-overexpression. PEH might improve the possibility of eradicating invasive cancer in the breast and axilla, especially in the luminal-B (HER2-positive) subtype. PEH is feasible and is not likely to increase the incidence of acute cardiac events compared to PCH. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-17.

Efficacy and Safety of Pemetrexed-Based Chemotherapy for Patients with Anthracycline-and Taxane-Resistant Breast Cancer

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

A Phase I/Ii and Pharmacogenomic Study of Pemetrexed and Cisplatin in Patients with Unresectable, Advanced Gastric Carcinoma

A Meta-Analysis of Combination Therapy Versus Single-Agent Therapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: Results from Nine Randomized Phase III Trials

Superior Outcome after Neoadjuvant Chemotherapy with Docetaxel, Anthracycline, and Cyclophosphamide Versus Docetaxel Plus Cyclophosphamide: Results from the NATT Trial in Triple Negative or HER2 Positive Breast Cancer

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

Pemetrexed Alone Regimen in Treatment of Advanced Chemo-Recurrent Non-Small Cell Lung Cancer

Efficacy and Safety of Pemetrexed Maintenance Chemotherapy for Advanced Non-Small Cell Lung Cancer in a Real-World Setting

Pd-L1 Expression Indicates Favorable Prognosis for Advanced Lung Adenocarcinoma Patients Treated with Pemetrexed

The Efficacy of Pemetrexed Combined Cis-platinum Chemotherapy for Patients with Advanced Non Small Cell Lung Cancer and the Effect on Serum Tumor Markers

Efficacy and safety of pemetrexed in advanced primary adenocarcinoma of lung

Retreatment with Pemetrexed-Based Chemotherapy in Advanced Nonsquamous NSCLC Patients.

A preliminary study on Pemetrexed combined with Oxaliplatin as second line therapy for patients with metastatic castration-resistant prostate cancer resistant to docetaxel or cabazitaxel plus prednisone

Clinical Study of Pemetrexed Maintenance Following Combination of Pemetrexed/carboplatin Chemotherapy for Advance Lung Adencarcinoma

Abstract P4-12-17: Pathological responses and heart safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy in clinical stage II-III, HER2-positive breast cancer patients: A phase 2, open-label, multicentre, randomised trial

Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination with Gefitinib or Erlotinib in Patients with Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study

Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases.

Efficacy and Safety of First-Line Pemetrexed Plus Carboplatin Followed by Single-Agent Pemetrexed Maintenance in Elderly Chinese Patients with Non-Squamous Non-Small-cell Lung Cancer

Gemcitabine based combination regimens for treatment of refractory advanced breast cancer

Rechallenge with Pemetrexed-Based Chemotherapy Improves the Survival of Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer.

The Effect of Paclitaxel Combined with Cisplatin on Advanced Breast Cancer